GABPβ1L Wakes Up TERT.

Gilbert J Rahme, Elizabeth Gaskell, Bradley E Bernstein

Open access · bronzeAbstract readComment

In one paragraph

Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact, top 86% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

Tert promotes cardiac regenerative repair after MI through alleviating ROS-induced DNA damage response in cardiomyocyte.Cell death discovery · 2024
Article

4 · The record

Corrections and comments

Comment on
Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner.2018

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Gilbert J RahmeDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.

Elizabeth GaskellDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.

Bradley E BernsteinDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address: bernstein.bradley@mgh.harvard.edu.

Broad Institute · US

Funding

Epigenetic Induction of Gliomagenesis in Neural Progenitor CellsF32CA236432 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI RAHME, GILBERT J · 2019 to 2021

$195k

NCI NIH HHS F32 CA236432

6 · The paper itself

Abstract

TERT catalyzes telomere maintenance. While silenced in most normal somatic cells, TERT is expressed in cancer, often due to promoter mutations, facilitating replicative immortality. In this issue of Cancer Cell, Mancini et al. demonstrate that GABPβ1L is required for mutant TERT promoter activity, thus identifying a potential therapeutic target.

Indexed as

GlioblastomaHumansMutationPromoter Regions, GeneticProtein IsoformsTelomeraseProtein IsoformsTelomeraseTERT protein, human

Identifiers

PMID30205042

DOI10.1016/j.ccell.2018.08.011

OpenAlexW2891037179

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.